Stopping DUX4-driven muscle damage in FSHD
Probing the activity of DUX4 in FSHD
Aiming to stop the harmful DUX4 protein from damaging muscles in people with FSHD.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11225149 on NIH RePORTER |
What this research studies
This project looks at how the DUX4 gene causes muscle damage in FSHD using lab experiments and a doxycycline-controlled mouse model that turns DUX4 on briefly. Researchers are studying proteins that bind to DUX4 and how DUX4 is degraded in cells, and they are testing a drug that blocks a helper protein called p300 (iP300w). The team also examines how short bursts of DUX4 change muscle-supporting cells and lead to scarring and weakness. Findings from these molecular and animal studies are intended to guide development of treatments that could be tested in people.
Who could benefit from this research
Good fit: Adults with genetically confirmed FSHD or documented DUX4-related disease would be the most likely candidates for future trials based on this work.
Not a fit: People whose muscle weakness is caused by other neuromuscular diseases or whose muscles are already severely fibrotic may not receive benefit.
Why it matters
Potential benefit: Could lead to therapies that reduce muscle injury and slow or prevent progression of FSHD.
How similar studies have performed: Prior lab and mouse-model work uncovered feedback regulators of DUX4 and produced a p300 inhibitor (iP300w) with promising preclinical effects, but human benefit has not yet been demonstrated.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Kyba, Michael — University of Minnesota
- Study coordinator: Kyba, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.